Disorder Related to Renal Transplantation Clinical Trial
Official title:
Prospective Controlled Protocol for 3 Months Steroid Withdrawal With Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
The investigators analyze the clinical outcome of steroid withdrawal protocol starting at 3 months after kidney transplantation using tacrolimus, Mycophenolate Mofetil (MMF), and basiliximab. This study is an open-label, prospective, controlled clinical trial in a single center. Those patients who fulfill the entry criteria could enter in this prospective controlled trial of steroid withdrawal three months after transplantation.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | July 2012 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged more than 13 years who received a primary kidney transplant - Subject who is using CNI ± purine synthesis inhibitor + steroid without change within the past 3 months (except the dosage) - serum creatinine < 2 mg/dL and the variation of serum creatinine < 30% during the past 3 months - Proteinuria = 1g quantified by 24 hour urine or spot urine protein/creatinine ratio < 1.0 - Subjects who agree with written informed consent Exclusion Criteria: - Subjects who received combined non-renal transplantation. - Subject who received re-transplantation - Deceased donor without a heartbeat - Patients with hypersensitivity to Mycophenolate sodium, Mycophenolate acid or Mycophenolate Mofetil or to any of the excipients. - Patient with HGPRT(Hypoxanthin e-guanine phosphoribosyl-transferase) such as Lesch-Nyhan syndrome and kelley-Seegmiller syndrome. - HLA-identical living related donor - ABO blood group incompatible - HIV, HBsAg, or HCV Ab tests (+) - Abnormal liver function test (AST or ALT or total bilirubin> upper normal limit x3) ANC < 1,500/µL or WBC < 2,500/µL or platelet < 750,000/µL - Women who are either pregnant, lactating, planning to become pregnant in the next 12 months. - Subjects with history of cancer, except successfully treated, localized nonmelanocytic skin cancer Subjects with clinically significant infections within the past 3 months. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Ajou University Hospital | Suwon |
Lead Sponsor | Collaborator |
---|---|
Ajou University School of Medicine |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the incidence of biopsy-confirmed acute rejection. | The primary efficacy variable was the incidence of biopsy-confirmed acute rejection. | 12 months | No |
Secondary | death, graft loss | The secondary efficacy variables included the cumulative incidence of a composite endpoint of death, and graft loss; | 12 months | No |
Secondary | adverse events and serious adverse events | The proportion of successfully steroid-withdrawn and steroid-free population at 6 months and at 12 months post-transplantation as well as the safety variables including the incidence of adverse events and serious adverse events, [blood pressure, lipid levels (total cholesterol), BUN (blood urea nitrogen) and blood glucose levels] | 6 months , 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
Terminated |
NCT01561404 -
Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise
|
Phase 4 | |
Recruiting |
NCT02849899 -
Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period
|
Phase 3 | |
Not yet recruiting |
NCT01289301 -
Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant
|
Phase 4 | |
Completed |
NCT00905957 -
Transversus Abdominis Plane Block For Renal Transplant Recipients
|
N/A | |
Active, not recruiting |
NCT02843867 -
Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation
|
||
Active, not recruiting |
NCT02751099 -
Bone and Cardiovascular Disease After Kidney Transplant
|
||
Completed |
NCT01744067 -
The Effects of Omega-3 Fatty Acids in Renal Transplantation
|
Phase 4 | |
Completed |
NCT01646099 -
Sun Protection of Kidney Transplant Recipients
|
N/A | |
Active, not recruiting |
NCT03935958 -
Curcumin in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT02513602 -
Osseointegrated Dental Implants in Kidney Transplanted Patients
|
N/A | |
Completed |
NCT01844713 -
Evaluation of Sun Protection Education for Kidney Transplant Recipients
|
N/A | |
Completed |
NCT02540395 -
Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation
|
N/A | |
Completed |
NCT01195194 -
Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.
|
Phase 4 | |
Completed |
NCT00724022 -
Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
|
Phase 4 | |
Terminated |
NCT00167661 -
Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03968588 -
Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation
|
Phase 4 | |
Recruiting |
NCT02515643 -
Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients
|
N/A | |
Completed |
NCT00455013 -
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT02843763 -
Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer
|
N/A |